Experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes.
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones leads a panel discussion on advances in therapy for estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer. Gradishar underscores the evolving treatment landscape, emphasizing the combination of endocrine and targeted therapies while considering specific mutations.
Vidal focuses on selective estrogen receptor degraders (SERDs), explaining their distinct mechanism compared with other anti-estrogen therapies. SERDs bind to receptors, facilitating their degradation and offering a unique approach. Vidal also mentions combination therapies with CDK4/6 inhibitors as part of targeted therapy strategies.
This expert dialogue provides crucial insights into the latest developments, particularly the role of oral SERDs, guiding clinicians in the dynamic field of metastatic breast cancer treatment.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More